The Latest Cardiac and Vascular News
NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more than 25,000 procedures in the registry. This significant milestone underscores […]
CHILLICOTHE, Ohio, Nov. 19, 2024 /PRNewswire/ — When something doesn’t feel right, you need expert care that’s close to home. Adena Health understands this, and that is why the experts with the Adena Heart and Vascular Institute and Adena Orthopedic and Spine Institute strive to deliver…
RapidAI’s leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 30, 2024 /PRNewswire/ — Recently Frost & Sullivan researched the…
PAIRS, Oct. 28, 2024 /PRNewswire/ — On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the…
NANJING, China, Oct. 25, 2024 /PRNewswire/ — On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with…
NEW YORK, Oct. 22, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a pioneer in stroke drug development, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation for CIRARA for the treatment of “large…
A First in the Middle East and North Africa
KFSHRC Launches Mobile Stroke Unit to Accelerate Patient Treatment
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
